文献速递乳腺MR

乳腺癌新辅助化疗后肌肉质量丢失:利用胸肌面积在乳腺磁共振成像上的评估

Muscle mass loss after neoadjuvant chemotherapy in breast cancer: estimation on breast magnetic resonance imaging using pectoralis muscle area.
PubMed 文献 · Eur Radiol · 2020-03-31

该回顾性研究纳入110例接受新辅助化疗的原发性乳腺癌患者,在标准化乳腺MRI上由两名放射科医生测量化疗前后的胸肌横截面积。化疗前胸肌面积为8.14 cm²,大于化疗后的7.03 cm²(p < 0.001)。胸肌面积变化与年龄、MRI间隔时间、受体状态、Ki-67、淋巴结状态、RECIST标准、组织学类型、平均病灶大小、分子分型和分级均无显著关系。

要点

  • 乳腺癌新辅助化疗后胸肌面积在标准化乳腺MRI上出现缩小,可反映骨骼肌质量丢失。
  • 化疗前胸肌面积为8.14 cm²,化疗后为7.03 cm²,差异有统计学意义(p < 0.001)。
  • 胸肌面积测量的阅片者间一致性(k = 0.72)和阅片者内一致性(0.69和0.71)均为良好。

核心结论

  • 乳腺癌患者接受新辅助化疗后胸肌面积会出现变化,该差异可直接在标准化乳腺MRI上评估。

研究设计与样本

  • 回顾性研究,经本院机构审查委员会批准,纳入2017年1月至2019年1月间110例连续接受新辅助化疗并经组织学证实为原发性乳腺癌、且用标准化乳腺MRI评估肿瘤反应的患者(平均年龄56 ± 11岁),由两名放射科医生在化疗前后测量胸肌横截面积。

关键影像表现/征象

  • 新辅助化疗前胸肌横截面积为8.14 cm²,化疗后为7.03 cm²(p < 0.001)。
  • 化疗前与化疗后MRI检查间隔时间为166.8 ± 50天。
  • 胸肌面积评估的阅片者间一致性k = 0.72,阅片者内一致性分别为0.69和0.71。

诊断标准与关键数值

  • 按RECIST标准,反应者(完全或部分缓解)与非反应者之间胸肌面积变化无显著差异(p = 0.362)。
  • 多变量回归分析显示ΔPMA与年龄、MRI检查间隔时间、雌激素和孕激素受体状态、人表皮生长因子受体2(HER-2)状态、Ki-67表达、淋巴结状态、RECIST标准、组织学类型、平均病灶大小、分子分型和分级均无显著关系。

临床应用与阅片要点

  • 在标准化乳腺MRI上可直接测量胸肌横截面积,用于评估新辅助化疗后的骨骼肌质量丢失。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: The loss of skeletal muscle mass is widely considered a predictor of poor survival and toxicity in breast cancer patients. The aim of this study is to evaluate if there is pectoralis muscle area (PMA) variation, reflecting loss of skeletal muscle mass, on consecutive MRI examinations after neoadjuvant chemotherapy.

METHODS: The retrospective study protocol was approved by our institutional review board. A total of n = 110 consecutive patients (mean age 56 ± 11 years) who were treated with neoadjuvant chemotherapy (NAC) for histologically proven primary breast cancer between January 2017 and January 2019 and in whom tumor response was checked with standard breast MRI were included. Two radiologists calculated the pectoralis muscle cross-sectional area before and after NAC.

RESULTS: Time between the MRI examinations, before starting NAC and after completing NAC, was 166.8 ± 50 days. PMA calculated pre-NAC (8.14 cm2) was larger than PMA calculated post-NAC (7.03 cm2) (p < 0.001). According to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria, there were no significant differences between responders (complete or partial response) and non-responders (p = 0.362). The multivariate regression analysis did not show any significant relationships between ΔPMA and age, time between MRI exams, estrogen and progesterone receptor status, human epidermal growth factor receptor status (HER-2), Ki-67 expression, lymph node status, RECIST criteria, histological type, average lesion size, molecular categories, and grade. Inter-reader (k = 0.72) and intra-reader agreement (0.69 and 0.71) in PMA assessment were good.

CONCLUSIONS: Pectoralis muscle mass varies in breast cancer patients undergoing NAC and this difference can be estimated directly on standard breast MRI.

KEY POINTS: • Pectoralis muscle area variation reflects loss of skeletal muscle mass. • Pectoralis muscle area on MRI is reduced after NAC. • Pectoralis muscle mass loss seems independent from other variables.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Rossi F, Torri L, Lambertini M, et al. Muscle mass loss after neoadjuvant chemotherapy in breast cancer: estimation on breast magnetic resonance imaging using pectoralis muscle area. Eur Radiol. 2020. PMID: 32232787. doi:10.1007/s00330-020-06799-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。